Literature DB >> 10227724

Gene expression of gastric type mucin (MUC5AC) in pancreatic tumors: its relationship with the biological behavior of the tumor.

S Yonezawa1, M Horinouchi, M Osako, M Kubo, S Takao, Y Arimura, K Nagata, S Tanaka, K Sakoda, T Aikou, E Sato.   

Abstract

Previously it has been found that the MUC2 gene for intestinal type secretory mucin is highly expressed in intraductal papillary mucinous tumors (IPMT), which are characterized by non-invasive growth and a favorable outcome. In contrast, MUC2 mRNA is rarely expressed in invasive ductal carcinomas (IDC), which have poor outcomes. The gastric type secretory mucin, MUC5AC, is strongly expressed in the surface mucous cells of gastric mucosa. As both MUC2 and MUC5AC mucins share the characteristics of forming highly viscous gels, it is expected that not only MUC2 mucin expression but also MUC5AC mucin expression may be associated with a favorable prognosis in patients with pancreatic tumors. MUC5AC mucin gene expression was examined in 24 cases of IPMT and 38 cases of IDC by in situ hybridization using a digoxigenin-labeled oligonucleotide. The results were compared with MUC2 mucin gene expression. Neither MUC5AC mRNA nor MUC2 mRNA was detected in normal pancreatic tissues. MUC5AC mRNA was expressed in 20 of 24 cases of IPMT (83%) and in five of 38 cases of IDC (13%). In contrast, MUC2 mRNA was expressed in 14 of 24 cases of IPMT (58%) and in none of the 38 cases of IDC (0%). The expression rates of MUC5AC mRNA and MUC2 mRNA in IPMT were significantly higher than those in IDC (P< 0.001, respectively). Intraductal papillary mucinous tumors are characterized by three histological types: (i) villous dark cell type; (ii) papillary clear cell type; and (iii) compact cell type. The villous dark cell type generally expressed both MUC5AC+ and MUC2+ genes. Alternatively, the papillary clear cell type and the compact cell type usually showed MUC5AC+ and MUC2- expression. Patients with MUC5AC mRNA expression had a significantly better survival prognosis than those with no MUC5AC mRNA expression (P< 0.005). In conclusion, MUC5AC gene expression occurs in a majority of IPMT cases, even in those with no MUC2 production. MUC5AC expression can be

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10227724     DOI: 10.1046/j.1440-1827.1999.00823.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  39 in total

1.  Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma.

Authors:  Olca Basturk; Michael F Berger; Hiroshi Yamaguchi; Volkan Adsay; Gokce Askan; Umesh K Bhanot; Ahmet Zehir; Fatima Carneiro; Seung-Mo Hong; Giuseppe Zamboni; Esra Dikoglu; Vaidehi Jobanputra; Kazimierz O Wrzeszczynski; Serdar Balci; Peter Allen; Naoki Ikari; Shoko Takeuchi; Hiroyuki Akagawa; Atsushi Kanno; Tooru Shimosegawa; Takanori Morikawa; Fuyuhiko Motoi; Michiaki Unno; Ryota Higuchi; Masakazu Yamamoto; Kyoko Shimizu; Toru Furukawa; David S Klimstra
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Intraductal papillary mucinous neoplasm (IPMN) of the gastric-type with focal nodular growth of the arborizing papillae: a case of high-grade transformation of the gastric-type IPMN.

Authors:  Shinichi Ban; Yoshihisa Naitoh; Fumihiro Ogawa; Yoshihiko Shimizu; Michio Shimizu; Akihiro Yasumoto; Isamu Koyama
Journal:  Virchows Arch       Date:  2006-04-26       Impact factor: 4.064

3.  Diagnostic and therapeutic implications of a novel immunohistochemical panel detecting duodenal mucosal invasion by pancreatic ductal adenocarcinoma.

Authors:  Sabrina C Sopha; Purva Gopal; Nipun B Merchant; Frank L Revetta; David V Gold; Kay Washington; Chanjuan Shi
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

4.  Precursor lesions of pancreatic cancer.

Authors:  Suguru Yonezawa; Michiyo Higashi; Norishige Yamada; Masamichi Goto
Journal:  Gut Liver       Date:  2008-12-31       Impact factor: 4.519

5.  Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study.

Authors:  Toru Furukawa; Günter Klöppel; N Volkan Adsay; Jorge Albores-Saavedra; Noriyoshi Fukushima; Akira Horii; Ralph H Hruban; Yo Kato; David S Klimstra; Daniel S Longnecker; Jutta Lüttges; G Johan A Offerhaus; Michio Shimizu; Makoto Sunamura; Arief Suriawinata; Kyoichi Takaori; Suguru Yonezawa
Journal:  Virchows Arch       Date:  2005-08-09       Impact factor: 4.064

6.  Non-invasive intraductal papillary neoplasms of the common bile duct: a clinicopathologic study of six cases.

Authors:  Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2012-09-05

Review 7.  Pathological features and diagnosis of intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Víctor M Castellano-Megías; Carolina Ibarrola-de Andrés; Guadalupe López-Alonso; Francisco Colina-Ruizdelgado
Journal:  World J Gastrointest Oncol       Date:  2014-09-15

Review 8.  MUC1 and MUC2 in pancreatic neoplasia.

Authors:  E Levi; D S Klimstra; A Andea; O Basturk; N V Adsay
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

9.  Mucin-producing bile duct tumor of the caudate lobe protruding into the common hepatic duct.

Authors:  Shuichiro Uchiyama; Kazuo Chijiiwa; Masahide Hiyoshi; Motoaki Nagano; Jiro Ohuchida; Koki Nagaike; Masahiro Kai; Kazuhiro Kondo
Journal:  J Gastrointest Surg       Date:  2007-11       Impact factor: 3.452

Review 10.  Malignant potential of intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Yoshiyuki Nakajima; Takatsugu Yamada; Masayuki Sho
Journal:  Surg Today       Date:  2010-08-26       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.